دورية أكاديمية
أعرض في EDS

Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts.

التفاصيل البيبلوغرافية
العنوان: Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts.
المؤلفون: Nimma R; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Kalvala AK; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Patel N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Surapaneni SK; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Sun L; Department of Biomedical Sciences, College of Medicine, Florida State University, 1115 West Call Street, Tallahassee, FL 32306, USA., Singh R; Department of Translational Science Laboratory, College of Medicine, Florida State University, 1115 West Call St., Tallahassee, FL 32306, USA., Nottingham E; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Bagde A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Kommineni N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Arthur P; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Nathani A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA., Meckes DG Jr; Department of Biomedical Sciences, College of Medicine, Florida State University, 1115 West Call Street, Tallahassee, FL 32306, USA., Singh M; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
المصدر: Pharmaceutics [Pharmaceutics] 2022 May 28; Vol. 14 (6). Date of Electronic Publication: 2022 May 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: The epidermal growth factor receptor (EGFR) is highly expressed in many non-small cell lung cancers (NSCLC), necessitating the use of EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatments. Osimertinib (OSM), a third-generation TKI, is routinely used in clinics, but T790M mutations in exon 20 of the EGFR receptor lead to resistance against OSM, necessitating the development of more effective therapeutics. Telmisartan (TLM), OSM, and cell cycle and apoptosis regulatory protein 1 (CARP-1) functional mimetic treatments (CFM4.17) were evaluated in this study against experimental H1975 tumor xenografts to ascertain their anti-cancer effects. Briefly, tumor growth was studied in H1975 xenografts in athymic nude mice, gene and protein expressions were analyzed using next-generation RNA sequencing, proteomics, RT-PCR, and Western blotting. TLM pre-treatment significantly reduced the tumor burden when combined with CFM-4.17 nanoformulation and OSM combination (TLM_CFM-F_OSM) than their respective single treatments or combination of OSM and TLM with CFM 4.17. Data from RNA sequencing and proteomics revealed that TLM_CFM-F_OSM decreased the expression of Lamin B2, STAT3, SOD, NFKB, MMP-1, TGF beta, Sox-2, and PD-L1 proteins while increasing the expression of AMPK proteins, which was also confirmed by RT-PCR, proteomics, and Western blotting. According to our findings, the TLM_CFM-F_OSM combination has a superior anti-cancer effect in the treatment of NSCLC by affecting multiple resistant markers that regulate mitochondrial homeostasis, inflammation, oxidative stress, and apoptosis.
References: Cancer Res. 2012 Sep 1;72(17):4394-404. (PMID: 22728651)
Oncotarget. 2015 Mar 30;6(9):6499-510. (PMID: 25894788)
Anticancer Res. 2021 Sep;41(9):4215-4228. (PMID: 34475041)
Mol Pharm. 2016 Jun 6;13(6):2049-58. (PMID: 27070720)
Cancers (Basel). 2014 Mar 26;6(2):708-22. (PMID: 24675568)
Protein Cell. 2013 Mar;4(3):176-85. (PMID: 23483479)
PLoS One. 2014 Mar 05;9(3):e89146. (PMID: 24598827)
Eur J Pharm Biopharm. 2021 Jan;158:172-184. (PMID: 33220423)
J Control Release. 1999 May 1;59(1):43-53. (PMID: 10210721)
Cancer Immunol Res. 2014 Sep;2(9):823-30. (PMID: 25187272)
J Korean Med Sci. 2020 Sep 07;35(35):e289. (PMID: 32893519)
Lancet Oncol. 2015 Sep;16(9):e447-e459. (PMID: 26370354)
Cell Death Dis. 2019 Aug 13;10(8):615. (PMID: 31409796)
Analyst. 2011 Feb 7;136(3):473-8. (PMID: 20967331)
Mol Cancer Ther. 2017 Jul;16(7):1257-1268. (PMID: 28446642)
J Clin Invest. 2002 Aug;110(4):475-82. (PMID: 12189241)
J Cell Sci. 2017 Jul 1;130(13):2087-2096. (PMID: 28668931)
Adv Cancer Res. 2018;138:71-98. (PMID: 29551130)
Nature. 2014 Jul 31;511(7511):543-50. (PMID: 25079552)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Acta Pharmacol Sin. 2021 Mar;42(3):451-459. (PMID: 32678313)
J Clin Oncol. 2011 May 20;29(15):2066-70. (PMID: 21482987)
Nat Med. 2015 Jun;21(6):560-2. (PMID: 25939061)
Molecules. 2014 Mar 05;19(3):2862-76. (PMID: 24603556)
Oncotarget. 2018 Jul 3;9(51):29680-29697. (PMID: 30038713)
J Physiol. 2006 Jul 1;574(Pt 1):63-71. (PMID: 16613876)
Exp Suppl. 2016;107:203-226. (PMID: 27812982)
PLoS One. 2015 Aug 24;10(8):e0136155. (PMID: 26301867)
Cells. 2021 Nov 19;10(11):. (PMID: 34831468)
Eur J Med Chem. 2018 Feb 25;146:460-470. (PMID: 29407971)
J Biol Chem. 2006 Oct 27;281(43):32207-16. (PMID: 16943194)
Mol Endocrinol. 2010 Sep;24(9):1748-64. (PMID: 20660302)
Nat Commun. 2013;4:2516. (PMID: 24084631)
Mol Biol Cell. 2004 Feb;15(2):922-33. (PMID: 14617800)
Proteomes. 2021 Mar 23;9(1):. (PMID: 33806881)
Onco Targets Ther. 2016 Sep 06;9:5489-93. (PMID: 27660466)
Oncol Rep. 2017 Nov;38(5):2825-2835. (PMID: 29048654)
N Engl J Med. 2009 Sep 3;361(10):958-67. (PMID: 19692684)
Lancet Oncol. 2010 Feb;11(2):121-8. (PMID: 20022809)
Front Cell Dev Biol. 2021 Sep 08;9:694363. (PMID: 34568317)
Oncogene. 2007 May 14;26(22):3279-90. (PMID: 17496922)
Nat Rev Drug Discov. 2009 Jan;8(1):33-40. (PMID: 19116625)
Adv Drug Deliv Rev. 2012 Jan;64(1):53-68. (PMID: 21983328)
Front Med. 2016 Dec;10(4):383-388. (PMID: 27770386)
Pharm Res. 2003 Sep;20(9):1485-95. (PMID: 14567645)
Nat Chem Biol. 2006 Dec;2(12):689-700. (PMID: 17108987)
Clin Chest Med. 2011 Dec;32(4):605-44. (PMID: 22054876)
Mol Cancer. 2013 May 02;12:35. (PMID: 23638878)
Mol Biol Rep. 2021 Mar;48(3):2365-2375. (PMID: 33792826)
Trends Pharmacol Sci. 2018 Jan;39(1):59-74. (PMID: 29153879)
Sci Rep. 2019 Dec 3;9(1):18177. (PMID: 31796785)
Nanomedicine (Lond). 2016 Jun;11(11):1377-92. (PMID: 27171485)
J Control Release. 2013 Nov 28;172(1):86-95. (PMID: 23838154)
Mol Cancer. 2020 Sep 24;19(1):145. (PMID: 32972405)
Mol Cancer. 2021 Jan 18;20(1):17. (PMID: 33461557)
Antioxidants (Basel). 2021 May 05;10(5):. (PMID: 34062984)
Curr Genomics. 2015 Oct;16(5):295-303. (PMID: 27047249)
Hum Mol Genet. 2019 Feb 1;28(3):351-371. (PMID: 30239736)
J Biol. 2003;2(4):28. (PMID: 14511394)
Sci Rep. 2021 Jun 14;11(1):12477. (PMID: 34127763)
Pharm Res. 2014 Oct;31(10):2796-809. (PMID: 24867421)
Carcinogenesis. 2017 Aug 1;38(8):766-780. (PMID: 28637319)
Front Immunol. 2019 Sep 25;10:2215. (PMID: 31611871)
Mol Cancer Ther. 2010 Nov;9(11):3003-14. (PMID: 20978159)
J Appl Physiol (1985). 1994 Sep;77(3):1281-7. (PMID: 7836132)
Biochem J. 2007 Apr 1;403(1):139-48. (PMID: 17147517)
Am J Pathol. 2007 May;170(5):1793-805. (PMID: 17456782)
Oncol Lett. 2018 Apr;15(4):5859-5864. (PMID: 29552215)
J Pharm Pharmacol. 2006 Mar;58(3):327-36. (PMID: 16536899)
Curr Biol. 2003 Nov 11;13(22):2004-8. (PMID: 14614828)
Sci Rep. 2021 Apr 9;11(1):7830. (PMID: 33837261)
J Cell Biochem. 2016 Jun;117(6):1279-87. (PMID: 26774024)
Nucleic Acids Res. 2019 Jul 2;47(W1):W234-W241. (PMID: 30931480)
Exp Cell Res. 2020 Aug 15;393(2):112090. (PMID: 32416090)
Br J Cancer. 2019 Oct;121(9):725-737. (PMID: 31564718)
Genome Biol. 2007;8(9):R183. (PMID: 17784955)
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35. (PMID: 14985505)
Pharmacol Rep. 2015 Oct;67(5):943-51. (PMID: 26398389)
CA Cancer J Clin. 2020 May;70(3):145-164. (PMID: 32133645)
Oncotarget. 2017 Aug 18;8(62):104813-104830. (PMID: 29285216)
Genomics Proteomics Bioinformatics. 2007 May;5(2):77-85. (PMID: 17893073)
Genes (Basel). 2018 Jun 20;9(6):. (PMID: 29925815)
Cancers (Basel). 2017 Sep 08;9(9):. (PMID: 28885561)
J Biol Chem. 2011 Nov 4;286(44):38000-38017. (PMID: 21903591)
Cancer Discov. 2013 Dec;3(12):1404-15. (PMID: 24065731)
Oncogene. 2006 Oct 30;25(51):6817-30. (PMID: 17072330)
Pharm Res. 2013 May;30(5):1435-46. (PMID: 23361589)
PLoS One. 2011;6(11):e27394. (PMID: 22102891)
معلومات مُعتمدة: G12 MD007582 United States MD NIMHD NIH HHS; U54 MD007582 United States MD NIMHD NIH HHS; 1735968 NSF-CREST Center for Complex Materials Design for Multidimensional Additive Processing (CoManD)
فهرسة مساهمة: Keywords: AMPK; Lamin B2; Osimertinib; RNA seq; RT-PCR; epidermal growth factor receptor; non-small cell lung cancer; proteomics
تواريخ الأحداث: Date Created: 20220624 Latest Revision: 20221127
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9230742
DOI: 10.3390/pharmaceutics14061156
PMID: 35745729
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics14061156